Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Shares Outstanding (Weighted Average) (2016 - 2025)

Fate Therapeutics' Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $118.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 4.49% year-over-year to $118.8 million; the TTM value through Dec 2025 reached $118.8 million, up 4.49%, while the annual FY2025 figure was $118.8 million, 4.49% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $118.8 million in Q4 2025 per FATE's latest filing, roughly flat from $118.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $118.8 million in Q4 2025 to a low of $93.4 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $104.0 million, with a median of $98.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 23.12% in 2021, then increased 0.74% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $94.7 million in 2021, then grew by 2.19% to $96.8 million in 2022, then grew by 1.64% to $98.4 million in 2023, then grew by 15.52% to $113.7 million in 2024, then increased by 4.49% to $118.8 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Shares Outstanding (Weighted Average) are $118.8 million (Q4 2025), $118.6 million (Q3 2025), and $118.5 million (Q2 2025).